Drug-induced Valvulopathy: An Update

Drug-induced valvulopathy is a serious liability for certain compound classes in development and for some marketed drugs intended for human use. Reports of valvulopathy led to the withdrawal of fenfluramines (anorexigens) and pergolide (antiparkinson drug) from the United States market in 1997 and 2007, respectively. The mechanism responsible for the pathogenesis of valvulopathy by these drugs is likely a result of an “off-target” effect via activation of 5-hydroxytryptamine (5-HT) 2B receptor (5-HT2BR) expressed on heart valve leaflets. Microscopically, the affected valve leaflets showed plaques of proliferative myofibroblasts in an abundant extracellular matrix, composed primarily of glycosaminoglycans. However, the valvular effects caused by fenfluramines and pergolide were not initially predicted from routine preclinical toxicity studies, and to date there are no specific validated animal models or preclinical/toxicologic screens to accurately predict drug-induced valvulopathy. This review covers the structure and function of heart valves and highlights major advances toward understanding the 5-HT2BR-mediated pathogenesis of the lesion and subsequently, development of appropriate animal models using novel techniques/experiments, use of functional screens against 5-HT2BR, and more consistent sampling and pathologic evaluation of valves in preclinical studies that will aid in avoidance of future drug-induced valvulopathy in humans.

[1]  B. Carabello,et al.  Valvular heart disease. , 1997, The New England journal of medicine.

[2]  A. Desmoulière,et al.  The Myofibroblast: one function, multiple origins , 2010 .

[3]  M. Yacoub,et al.  Molecular characterization of interstitial cells isolated from human heart valves. , 2000, The Journal of heart valve disease.

[4]  V. Ferrans,et al.  35 – Cardiovascular and Skeletal Muscle Systems , 2002 .

[5]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[6]  R. Levy,et al.  Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. , 2009, The American journal of pathology.

[7]  A. Gotlieb,et al.  Cell biology of valvular interstitial cells. , 1996, The Canadian journal of cardiology.

[8]  R. Sorelle Diet drug maker agrees to $3.75 billion settlement. , 1999, Circulation.

[9]  Frederick J Schoen,et al.  New frontiers in the pathology and therapy of heart valve disease: 2006 Society for Cardiovascular Pathology, Distinguished Achievement Award Lecture, United States-Canadian Academy of Pathology, Atlanta, GA, February 12, 2006. , 2006, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[10]  C. Yeh,et al.  Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. , 2009, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[11]  I. Gessner,et al.  Effects of prenatal co-administration of phentermine and dexfenfluramine in rats. , 1999, European journal of pharmacology.

[12]  K. Miyazono,et al.  Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. , 1993, The American journal of pathology.

[13]  Bryan L. Roth,et al.  Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment , 2009, Molecular Pharmacology.

[14]  P. A. Wallenborn,et al.  Agammaglobulinemia , 1960 .

[15]  E. Hay,et al.  Cell Biology of Extracellular Matrix , 1988, Springer US.

[16]  G. Mazzotti,et al.  Trends in ecstasy use in the United States from 1995 to 2001: comparison with marijuana users and association with other drug use. , 2005, Experimental and clinical psychopharmacology.

[17]  F. Barry Proteoglycans: structure and function. , 1990, Biochemical Society transactions.

[18]  P. Franken,et al.  Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. , 2007, The American journal of cardiology.

[19]  A. Bossuyt,et al.  In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. , 2007, European heart journal.

[20]  J. Van Dorpe,et al.  Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. , 1996, The Journal of heart valve disease.

[21]  V. Setola,et al.  Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen–phen’ , 2005, Expert opinion on drug metabolism & toxicology.

[22]  Elaine L. Lee,et al.  Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. , 2009, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[23]  R. Markwald,et al.  An In Vivo Analysis of Hematopoietic Stem Cell Potential: Hematopoietic Origin of Cardiac Valve Interstitial Cells , 2006, Circulation research.

[24]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[25]  Ut Southwestern Pergolide use in Parkinson disease is associated with cardiac valve regurgitation , 2005 .

[26]  Kristi S Anseth,et al.  Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 interactions with matrix molecules. , 2005, Matrix biology : journal of the International Society for Matrix Biology.

[27]  M. Yacoub,et al.  Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. , 2000, The Journal of heart valve disease.

[28]  A. Verma Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease , 2008 .

[29]  Nicola Fox,et al.  Cardiovascular system. , 2007, Nursing Standard.

[30]  F. Schoen,et al.  Human Semilunar Cardiac Valve Remodeling by Activated Cells From Fetus to Adult: Implications for Postnatal Adaptation, Pathology, and Tissue Engineering , 2006, Circulation.

[31]  Frederick J Schoen,et al.  Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. , 2005, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[32]  P. Lantelme,et al.  Valvular heart disease associated with fenfluramine detected 7 years after discontinuation of treatment. , 2007, The Annals of thoracic surgery.

[33]  K. J. Grande-Allen,et al.  Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading. , 2004, Glycobiology.

[34]  D. Mulholland,et al.  Cardiac valve interstitial cells: regulator of valve structure and function. , 1997 .

[35]  R. Lipton,et al.  Age-dependent prevalence and clinical features of migraine , 2006, Neurology.

[36]  R. Visse,et al.  Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases : Structure , 2003 .

[37]  P. Libby,et al.  Activated Interstitial Myofibroblasts Express Catabolic Enzymes and Mediate Matrix Remodeling in Myxomatous Heart Valves , 2001, Circulation.

[38]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.

[39]  F. Viallet,et al.  Fibrotic valvular heart disease subsequent to bromocriptine treatment. , 2002, Cardiology in review.

[40]  K. A. Misch Development of heart valve lesions during methysergide therapy. , 1974, British medical journal.

[41]  M. Millan,et al.  Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[42]  R. Horowski,et al.  Agonism at 5-HT2B receptors is not a class effect of the ergolines. , 2005, European journal of pharmacology.

[43]  Frederick J. SchoenT Review Article Cardiac valves and valvular pathology B Update on function, disease, repair, and replacement , 2005 .

[44]  P. Franken,et al.  Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. , 2009, American journal of physiology. Heart and circulatory physiology.

[45]  A. Gotlieb,et al.  Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells. , 2008, The American journal of pathology.

[46]  M. Hamon,et al.  Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice , 2005, Circulation.

[47]  A. Verma,et al.  Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation , 2008 .

[48]  V. Joag,et al.  The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. , 2007, The American journal of pathology.

[49]  Hans Kresse,et al.  Proteoglycans of the extracellular matrix and growth control , 2001, Journal of cellular physiology.

[50]  H. Schoon,et al.  Distribution of extracellular matrix components in normal and degenerated canine tricuspid valve leaflets. , 2009, Journal of comparative pathology.

[51]  W. Edwards,et al.  Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. , 2001, The Journal of heart valve disease.

[52]  W. Edwards,et al.  Valvular heart disease in patients taking pergolide. , 2002, Mayo Clinic proceedings.

[53]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[54]  H. Jick Heart valve disorders and appetite-suppressant drugs. , 2000, JAMA.

[55]  A. Tajik,et al.  Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations , 1992, Annals of Internal Medicine.

[56]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[57]  Craig A Simmons,et al.  Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. , 2009, The American journal of pathology.

[58]  C. Elangbam,et al.  5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[59]  R. Levy,et al.  Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. , 2002, The American journal of pathology.

[60]  A. Fishman Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.

[61]  P. Greaves Comprar Histopathology of Preclinical Toxicity Studies, 3rd Edition. Interpretation and Relevance in Drug Safety Evaluation | Peter Greaves | 9780444527714 | Elsevier Science , 2007 .

[62]  G. Kissling,et al.  Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy--a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[63]  Craig A. Simmons,et al.  Spatial Heterogeneity of Endothelial Phenotypes Correlates With Side-Specific Vulnerability to Calcification in Normal Porcine Aortic Valves , 2005, Circulation research.

[64]  Gerard C Blobe,et al.  Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.

[65]  B L Bass,et al.  Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. , 1994, The Journal of surgical research.

[66]  R. M. Lightfoot,et al.  5-Hydroxytryptamine (5HT) Receptors in the Heart Valves of Cynomolgus Monkeys and Sprague-Dawley Rats , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[67]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[68]  M. Lopez-Ilasaca Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. , 1998, Biochemical pharmacology.

[69]  T. Ryan,et al.  Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. , 2000, Circulation.

[70]  L. Leinwand,et al.  Valvular Myofibroblast Activation by Transforming Growth Factor-&bgr;: Implications for Pathological Extracellular Matrix Remodeling in Heart Valve Disease , 2004, Circulation research.

[71]  C. Pollick Aminorex to Fen/Phen: an epidemic foretold. , 1999, Circulation.

[72]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[73]  Robert M. Nerem,et al.  Transcriptional Profiles of Valvular and Vascular Endothelial Cells Reveal Phenotypic Differences: Influence of Shear Stress , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[74]  R. Khokha,et al.  Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors , 2005, Thrombosis and Haemostasis.

[75]  R. Fossmark,et al.  Long-Term Serotonin Administration Induces Heart Valve Disease in Rats , 2005, Circulation.

[76]  W. Weidman Second natural history study of congenital heart defects. , 1993, Circulation.

[77]  Karen Birmingham,et al.  the heart , 2002, Nature.

[78]  M R de Leval,et al.  Innervation of human atrioventricular and arterial valves. , 1996, Circulation.

[79]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[80]  Giulio Gabbiani,et al.  Perspective Article: Tissue repair, contraction, and the myofibroblast , 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[81]  P. Hopkins,et al.  Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals , 2008, BMC medicine.

[82]  K. Miyazono,et al.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins. , 1997, Nature.

[83]  R. Rothman,et al.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy. , 2009, American journal of therapeutics.

[84]  M. Worsham,et al.  Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[85]  F. Grandas,et al.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review , 2009, Journal of Neural Transmission.

[86]  K. Donnelly Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases , 2008, Toxicologic pathology.

[87]  W. Poewe,et al.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.

[88]  J. F. Keane,et al.  Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. , 1993, Circulation.

[89]  J. Graham Cardiac and pulmonary fibrosis during methysergide therapy for headache. , 1967, Transactions of the American Clinical and Climatological Association.

[90]  H. Schoon,et al.  Histomorphological findings and expression of matrix metalloproteinases and their tissue specific inhibitors (TIMPs) in normal tricuspid valves and in chronic tricuspid valvular disease in dogs. , 2010, Veterinary journal.

[91]  R. Markwald,et al.  Periostin regulates atrioventricular valve maturation. , 2008, Developmental biology.

[92]  A. J. Hauck,et al.  Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. , 1990, Archives of pathology & laboratory medicine.

[93]  T. Ryan,et al.  Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. , 2002, American heart journal.

[94]  P. Greaves 7 – Cardiovascular System , 2007 .

[95]  D. Heistad,et al.  Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. , 2009, American journal of physiology. Heart and circulatory physiology.

[96]  H. Schoon,et al.  An immunohistochemical study of the role of matrix metalloproteinases and their tissue inhibitors in chronic mitral valvular disease (valvular endocardiosis) in dogs. , 2009, Veterinary journal.

[97]  B. McManus,et al.  Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? , 2002, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[98]  A. Gotlieb,et al.  Cardiac valve interstitial cells secrete fibronectin and form fibrillar adhesions in response to injury. , 2007, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[99]  D. E. Nichols,et al.  Serotonin receptors. , 2008, Chemical reviews.

[100]  V. Setola,et al.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. , 2003, Molecular pharmacology.

[101]  B. Fanburg,et al.  A new role for an old molecule: serotonin as a mitogen. , 1997, The American journal of physiology.

[102]  A. Feldman,et al.  Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. , 2000, Cardiovascular research.

[103]  S. Bressler,et al.  The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. , 2004, Critical reviews in eukaryotic gene expression.

[104]  Patrick Santens,et al.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease , 2004, The Lancet.

[105]  R. Iozzo,et al.  The role of decorin in collagen fibrillogenesis and skin homeostasis , 2002, Glycoconjugate Journal.

[106]  T. Wight,et al.  Versican: a versatile extracellular matrix proteoglycan in cell biology. , 2002, Current opinion in cell biology.

[107]  Keith E. Volmar,et al.  Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. , 2001, Archives of pathology & laboratory medicine.

[108]  B. Roth Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[109]  G. Bray,et al.  Obesity , 2008, Annals of Internal Medicine.

[110]  W. Chitwood,et al.  Histologic changes in three explanted native cardiac valves following use of fenfluramines. , 1999, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[111]  P. Lecompte,et al.  Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. , 1974, American heart journal.